Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

CDSCO modifies norms for testing permissions to speed up drug approvals

February 26, 2026 8 min read Science & Technology Polity & Governance GS Paper 3 (Science & Technology Pharmaceuticals Healthcare Governance)
On This Page ▼

What Happened

  • The Central Drugs Standard Control Organisation (CDSCO) announced modifications to the process for granting No Objection Certificates (NOCs) for laboratory testing of drug samples, with the changes coming into effect from June 1, 2026.
  • Under the revised norms, any NOC for testing of drug samples at designated government laboratories will be issued immediately upon receipt of applications — eliminating the earlier practice of detailed pre-scrutiny before granting permission.
  • Previously, CDSCO examined detailed product specifications submitted by applicants before issuing testing permissions — including type of formulation, dosage form, Critical Quality Attributes (CQAs), product development reports, forced degradation studies, and other technical data.
  • Under the new system, applicants must submit finalised regulatory specifications upfront at the time of applying, based on prevailing Pharmacopoeia standards and their own Quality Management System (QMS) — shifting the technical scrutiny to a later stage rather than front-loading it as a gate for testing.
  • The move is aimed at reducing the time taken between application and the commencement of laboratory testing, thereby speeding up the overall drug approval timeline for both imported and domestically manufactured drugs.
  • This change is part of a broader push to streamline pharmaceutical regulations under the New Drugs and Clinical Trials (Amendment) Rules, 2026 and to make India a more competitive destination for drug development and clinical research.

Static Topic Bridges

CDSCO — India's National Drug Regulatory Authority

The Central Drugs Standard Control Organisation (CDSCO) functions as India's National Regulatory Authority (NRA) for pharmaceuticals and medical devices. It operates under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare. The Drugs Controller General of India (DCGI) heads CDSCO and is the apex drug regulatory official.

CDSCO's mandate under the Drugs and Cosmetics Act, 1940: - Approval of new drugs and clinical trials - Laying down standards for drug quality (in conjunction with the Indian Pharmacopoeia Commission) - Regulating the quality of imported drugs - Licensing of blood and blood products, vaccines, and certain biologicals - Coordination with State Drug Control Organisations for uniform enforcement

CDSCO has its headquarters in New Delhi and operates through 8 Zonal Offices, 6 Sub-Zonal Offices, 8 Central Drug Testing Laboratories (CDTLs), and 16 Port Offices. It is advised by two statutory bodies: the Drug Technical Advisory Board (DTAB) — the apex technical advisory body — and the Drug Consultative Committee (DCC) for uniformity of drug control across states.

  • Parent legislation: Drugs and Cosmetics Act, 1940; Drugs and Cosmetics Rules, 1945
  • DCGI: statutory authority under Section 8 of the Drugs and Cosmetics Act
  • Also governs: Medical Devices Rules, 2017; New Drugs and Clinical Trials (NDCT) Rules, 2019; Cosmetics Rules, 2020
  • Approves Schedule H and Schedule X drugs (prescription-only and controlled substances)
  • Grants permission for clinical trials under Chapter V of the NDCT Rules, 2019
  • Drug Technical Advisory Board (DTAB): advises Central Government on technical matters; meetings mandatory before major regulatory changes

Connection to this news: The NOC modification is a CDSCO administrative decision that does not require a legislative change — it adjusts the internal scrutiny process. However, the broader New Drugs and Clinical Trials (Amendment) Rules, 2026 under which it sits do involve formal rule-making under the Drugs and Cosmetics Act, requiring DTAB consultation.

Drugs and Cosmetics Act, 1940 — Regulatory Architecture

The Drugs and Cosmetics Act, 1940 is the foundational legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India. Passed during the colonial period and extensively amended since, it establishes a dual regulatory structure where the Central Government (through CDSCO/DCGI) and State Governments (through State Drug Controllers/SDCs) share jurisdiction.

Key structural features: - Schedule Y (now subsumed in NDCT Rules, 2019): laid down requirements for clinical trial data for new drug approval - New Drugs and Clinical Trials Rules, 2019: replaced Schedule Y; streamlined clinical trial requirements; introduced deemed approval timelines (30 days for orphan drugs, 12 weeks for accelerated approval) - First-in-class global clinical trials: India now permits simultaneous Phase I/II/III trials for drugs being developed globally, removing the earlier requirement of foreign Phase I data before Indian trials - Indian Pharmacopoeia (IP): published by the Indian Pharmacopoeia Commission (IPC), Ghaziabad; sets quality standards for drugs in India; references to IP are the legal basis for drug quality specifications

  • Drugs and Cosmetics Act, 1940: 128 sections, 24 Schedules
  • Schedule H drugs: sold only on prescription; must not be dispensed more than the quantity prescribed
  • Schedule H1 drugs: psychotropic substances requiring additional record-keeping
  • 2019 NDCT Rules: introduced maximum 30-working-day timeline for reviewing clinical trial applications (CTA)
  • Indian Pharmacopoeia Commission: statutory body under Ministry of Health; publishes IP every 5 years (latest: IP 2022)
  • Central Drug Testing Laboratories: government labs that test submitted samples for quality parameters during approval process

Connection to this news: The revised NOC process for testing permissions directly involves the Central Drug Testing Laboratories. By allowing immediate NOC issuance, CDSCO is decoupling the administrative permission step from the technical scrutiny step — a process innovation within the existing legislative framework of the Drugs and Cosmetics Act.

India's Pharmaceutical Sector — Global Position and Policy Context

India is the world's third-largest pharmaceutical producer by volume and holds approximately 20% of the global generics market by volume. The sector contributes around $27 billion in exports annually (2023-24), making it one of India's top export earners. "Pharmacy of the World" is a widely used descriptor reflecting India's role as a key supplier of generic medicines to developing countries and multilateral procurement agencies.

India's pharmaceutical competitiveness depends on regulatory efficiency — delays in approvals translate to delayed market entry, lost export windows, and higher costs. Key regulatory bottlenecks historically identified: - Long approval timelines (CDSCO average new drug approval: 12-24 months vs. US FDA target of 12 months) - Sequential rather than parallel review processes - Mandatory waiting for foreign Phase I data before domestic trials (removed by NDCT Rules, 2019) - Manual/paper-heavy submission processes (being digitised via SUGAM portal)

Government initiatives to strengthen pharma: - Pharmaceuticals & Medical Devices Policy 2017: targets India as global pharma hub - Production Linked Incentive (PLI) scheme for pharmaceuticals: Rs. 15,000 crore for bulk drugs (APIs) and finished dosage forms - Scheme for Promotion of Bulk Drug Parks: reduces API import dependence (India imports ~70% of APIs from China)

  • India: third-largest pharma producer globally by volume; second-largest by number of US FDA-approved plants outside the US
  • Generics market: India supplies ~50% of Africa's drug requirements and ~40% of US generic drug requirements
  • SUGAM portal: CDSCO's online drug approval and licensing platform
  • PLI for pharma: approved June 2021; target 41 selected pharmaceutical companies; minimum incremental sales threshold-based incentives
  • API import from China: ~68-70% of India's API requirements; identified as strategic vulnerability post-COVID-19

Connection to this news: The NOC modification is a targeted operational reform addressing one specific bottleneck in the approval chain. It fits within the broader strategic priority of reducing regulatory friction for India's pharmaceutical sector — particularly for companies seeking to test new formulations for both domestic market approval and export registration in regulated markets (US, EU, WHO prequalification).

Quality Management in Pharmaceuticals — GMP and Pharmacopoeia Standards

Good Manufacturing Practice (GMP) and pharmacopoeia compliance are the twin pillars of pharmaceutical quality assurance. The Drugs and Cosmetics Rules, 1945, Schedule M sets out GMP requirements for pharmaceutical manufacturers in India. The World Health Organization's (WHO) prequalification programme and the US FDA's registration process both require GMP compliance verified through inspections.

The new CDSCO norm requires applicants to base their testing specifications on: 1. Prevailing Pharmacopoeia standards (Indian Pharmacopoeia, British Pharmacopoeia, United States Pharmacopeia) and relevant general chapters listed in the Second Schedule of the Drugs and Cosmetics Act, 1940 2. A Product-Specific Quality Management System (QMS) — a documented system ensuring consistency between the development process and the submitted specifications

  • Indian Pharmacopoeia (IP): monographs for ~3,500 drugs; published by IPC under Ministry of Health
  • Schedule M of D&C Rules: prescribes GMP for pharmaceutical manufacturing units; aligned with WHO GMP guidelines (2014)
  • Critical Quality Attributes (CQAs): physical, chemical, biological properties critical to product quality (e.g., potency, purity, dissolution rate)
  • Quality Management System (QMS): ISO 9001 / ICH Q10 pharmaceutical quality system guidelines
  • WHO prequalification: mandatory for supplying medicines to UNICEF, Global Fund, PEPFAR procurement — key for Indian pharma exports
  • ICH (International Council for Harmonisation): sets globally harmonised pharmaceutical quality, safety, and efficacy guidelines; India became member in 2016

Connection to this news: The shift to upfront, complete specification submission under the new CDSCO norms incentivises companies to prepare more rigorous, pharmacopoeia-compliant specification documents before applying — rather than submitting incomplete data for iterative pre-scrutiny. This places greater responsibility on applicants but removes a gatekeeping step that slowed file movement without adding testing quality.

Key Facts & Data

  • Issuing authority: Central Drugs Standard Control Organisation (CDSCO), under Ministry of Health and Family Welfare
  • Change: Immediate NOC issuance for laboratory testing upon application receipt — eliminating pre-scrutiny of detailed product specifications
  • Effective date: June 1, 2026
  • Part of: New Drugs and Clinical Trials (Amendment) Rules, 2026
  • Applicants must now submit: finalised regulatory specifications based on Pharmacopoeia standards and product-specific QMS upfront
  • Earlier requirement (removed): detailed product development reports, forced degradation studies, Critical Quality Attributes (CQAs), dosage form data before NOC
  • Governing legislation: Drugs and Cosmetics Act, 1940; New Drugs and Clinical Trials (NDCT) Rules, 2019 (as amended 2026)
  • CDSCO structure: HQ New Delhi; 8 Zonal Offices; 6 Sub-Zonal Offices; 8 Central Drug Testing Laboratories; 16 Port Offices
  • India's pharma export value: ~$27 billion (2023-24); world's third-largest pharma producer by volume
  • India supplies ~50% of Africa's drug needs and ~40% of US generics by volume
  • API vulnerability: India imports ~68-70% of active pharmaceutical ingredients from China